PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 403/12, A61K 31/40

A1

(11) International Publication Number: WO 98/23610

(43) International Publication Date: 4 June 1998 (04.06.98)

(21) International Application Number: PCT/US97/20801

(22) International Filing Date: 21 November 1997 (21.11.97)

(30) Priority Data:
60/031,777 25 November 1996 (25.11.96) US

(71) Applicant *(for all designated States except US)*: THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: HENRY, Raymond, Todd [US/US]; 877 Hechterman Road, Pleasant Plain, OH 45162 (US). SHELDON, Russell, James [US/US]; 5023 Winton Road, Fairfield, OH 45014 (US). SEIBEL, William, Lee [US/US]; 5704 Somerset Drive, Hamilton, OH 45011 (US).

(74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217 (US).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: 2–IMIDAZOLINYLAMINOINDOLE COMPOUNDS USEFUL AS ALPHA–2 ADRENOCEPTOR AGONISTS

(57) Abstract

This invention involves compounds having structure (I) wherein: a) R_1 is hydrogen; or alkyl; bond (a) is a single or a double bond; b) R_2 and R_3 are each independently selected from hydrogen; unsubstituted C_1–C_3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted C_1–C_3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C_1–C_3 alkylamino or C_1–C_3 dialkylamino and halo; c) R_4, R_5 and R_6 are each independently selected from hydrogen; unsubstituted C_1–C_3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted C_1–C_3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C_1–C_3 alkylamino or C_1–C_3 dialkylamino; halo; and 2–imidazolinylamino; and wherein one and only one of R_4, R_5 and R_6 is 2–imidazolinylamino; d) R_7 is selected from hydrogen; unsubstituted C_1–C_3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted C_1–C_3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C_1–C_3 alkylamino or C_1–C_3 dialkylamino and halo; e) the compound is not 4–(2–imidazominylamino)indole; enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha–2 adrenoceptors.



(I)